-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 25, Hengrui announced that its subsidiary Beijing Shengdi Pharmaceutical's class 1 new drug SHR-2004 injection was approved for clinical use, and it is intended to be used for the prevention or treatment of arteriovenous thrombosis
.
According to data from Minet.
com, the sales of terminal antithrombotic drugs in China's public medical institutions will exceed 30 billion yuan in 2020.
At present, Hengrui has 3 antithrombotic drugs approved for marketing, among which fondaparinux sodium injection has won the first place.
Seven batches of admission tickets are collected
.
SHR-2004 Injection Approved Clinical Situation Source: CDE official website According to the announcement, SHR-2004 injection is a macromolecular biological preparation, which is intended to be used for the prevention or treatment of arteriovenous thrombosis
.
Up to now, SHR-2004 injection-related projects have invested about 21.
27 million yuan in research and development
.
According to the data of Minet.
com, in addition to SHR-2004 injection, Hengrui's other class 1 antithrombotic drug SHR2285 tablets has entered the clinical phase I stage
.
At present, Hengrui's listed antithrombotic drugs include ticlopidine hydrochloride tablets, fondaparinux sodium injection and aspirin dipyridamole sustained-release capsules
.
In recent years, driven by the national procurement of stents, the antithrombotic drug market has ushered in a new growth opportunity
.
According to data from Minet.
com, in 2020, the sales of terminal antithrombotic drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 30 billion yuan.
A slight decline, more than 17 billion yuan in the first half of 2021, a year-on-year increase of 13.
89%
.
However, the head market is mainly occupied by overseas companies such as Bayer, Sanofi and Boehringer Ingelheim
.
Market sales of terminal antithrombotic drugs in public medical institutions in China (unit: ten thousand yuan) Source: Minet.
com Six antithrombotic drugs, including clopidogrel bisulfate tablets, ticagrelor tablets, and bivalirudin for injection, have been included in the collection.
Companies such as Sanofi, Lepu, CSPC and Xinlitai were selected
.
In the upcoming seventh batch of centralized collection, three anti-thrombotic drugs, fondaparinux sodium injection, tirofiban injection and eptifibatide injection, have been included in the collection scope.
Hengrui’s fondaparinux sodium injection Injectables have taken admission
.
Source: CDE official website, Minet database, corporate announcement
.
According to data from Minet.
com, the sales of terminal antithrombotic drugs in China's public medical institutions will exceed 30 billion yuan in 2020.
At present, Hengrui has 3 antithrombotic drugs approved for marketing, among which fondaparinux sodium injection has won the first place.
Seven batches of admission tickets are collected
.
SHR-2004 Injection Approved Clinical Situation Source: CDE official website According to the announcement, SHR-2004 injection is a macromolecular biological preparation, which is intended to be used for the prevention or treatment of arteriovenous thrombosis
.
Up to now, SHR-2004 injection-related projects have invested about 21.
27 million yuan in research and development
.
According to the data of Minet.
com, in addition to SHR-2004 injection, Hengrui's other class 1 antithrombotic drug SHR2285 tablets has entered the clinical phase I stage
.
At present, Hengrui's listed antithrombotic drugs include ticlopidine hydrochloride tablets, fondaparinux sodium injection and aspirin dipyridamole sustained-release capsules
.
In recent years, driven by the national procurement of stents, the antithrombotic drug market has ushered in a new growth opportunity
.
According to data from Minet.
com, in 2020, the sales of terminal antithrombotic drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 30 billion yuan.
A slight decline, more than 17 billion yuan in the first half of 2021, a year-on-year increase of 13.
89%
.
However, the head market is mainly occupied by overseas companies such as Bayer, Sanofi and Boehringer Ingelheim
.
Market sales of terminal antithrombotic drugs in public medical institutions in China (unit: ten thousand yuan) Source: Minet.
com Six antithrombotic drugs, including clopidogrel bisulfate tablets, ticagrelor tablets, and bivalirudin for injection, have been included in the collection.
Companies such as Sanofi, Lepu, CSPC and Xinlitai were selected
.
In the upcoming seventh batch of centralized collection, three anti-thrombotic drugs, fondaparinux sodium injection, tirofiban injection and eptifibatide injection, have been included in the collection scope.
Hengrui’s fondaparinux sodium injection Injectables have taken admission
.
Source: CDE official website, Minet database, corporate announcement
